Safety Study of Continuing Versus Interrupting Direct Oral Anticoagulants DOAC in Adults Undergoing Elective Coronary Angiography or Percutaneous Coronary Intervention
Led by Zuyderland Medisch Centrum · Updated on 2026-05-29
1270
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Patients with atrial fibrillation AF often also have coronary artery disease CAD, and many require coronary stenting. Direct Oral Anticoagulants DOAC are commonly used to prevent blood clots in AF patients, replacing older Vitamin-K Antagonists. This trial investigates the safety of continuing DOAC treatment without interruption during elective invasive coronary angiography ICA or percutaneous coronary intervention PCI, as current guidelines recommend stopping DOACs 24-48 hours before these procedures but are based on limited evidence. The study is a prospective, multicenter, randomized trial focused on assessing bleeding risks related to uninterrupted DOAC use.
CONDITIONS
Brief Title
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention
Research Team
S
Sanne Janssen, MSC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients aged over 18 years using DOAC and undergoing elective invasive coronary angiography or percutaneous coronary intervention
Provided signed informed consent
You will not qualify if you...
Patients initially presenting with Acute Coronary Syndrome (STEMI, NSTEMI, UA)
Patients under 18 years old
Calculated creatinine clearance less than 30 mL/min
Patients simultaneously participating in another clinical trial
Major surgical procedure within 30 days before the procedure
Known inaccessible radial artery during previous procedure
History of gastrointestinal bleeding in the previous 6 months
History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding
Chronic bleeding disorder
Known intracranial neoplasm, arteriovenous malformation, or aneurysm
Known anemia with last measured haemoglobin value less than 6 mmol/L [9.67 g/dL]
Current pregnancy or breast-feeding
Known significant liver disease (e.g., acute clinical hepatitis, chronic active hepatitis, cirrhosis), or Alanine aminotransferase (ALT) greater than 3 times the upper limit of normal
Participation in another clinical trial
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 1 day
Participants undergo elective invasive coronary angiography or percutaneous coronary intervention while either continuing or interrupting their DOAC medication as per their group assignment.
1 procedure visit (in-person)
Follow-up
Duration - 30 days
Participants are monitored for safety and complications including bleeding and thromboembolic events for 30 days after the procedure. They are also asked to complete a questionnaire about their experience.
1 follow-up visit and 1 questionnaire
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Comparing 24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent Placement in Patients With High Lipoproteina Levels
Using 320-Detector CT to Measure Heart Tissue Fibrosis in Adults with Atrial Fibrillation
Before Catheter Ablation Treatment
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Study of Implantable Cardioverter Defibrillator Benefits in Adults with Coronary Artery Disease and Ventricular Fibrillation After Complete Revascularization
Randomized Double-Blind Study Evaluating Intravenous YN001 Versus Placebo in Adults With Coronary Atherosclerosis Receiving Cardiovascular Risk Therapy
Validating the ABCD-GENE Score to Identify Stable Coronary Artery Disease Patients Undergoing Elective PCI at Risk of Heart Injury During Procedure
Real-World Registry of Quantitative Flow Ratio-Guided Coronary Revascularization and Quality Evaluation Across Multiple Centers in China
Evaluating Coronary CT Angiography to Guide Calcium Modification Compared to Intravascular Ultrasound in Treating Calcified Coronary Artery Disease A Multicenter Randomized Trial
Study on Ultrasound Screening and Combined Treatments for Patients With Coronary and Head and Neck Artery Narrowing
Long-Term Safety and Effectiveness Evaluation of the VARIPULSE Catheter System in Symptomatic Paroxysmal Atrial Fibrillation Management
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Direct oral anticoagulation interruption vs continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: Design and rationale of the South Limburg Myocardial Infarction Study Group Trial 2 (SLIM-2).
Sanne Janssen, Jasper J P Luijkx, Wouter Swinnen...